CINECA IRIS Institutional Research Information System

Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial. Since then few real-life data are available.

Multicentric EORTC retrospective study shows efficacy of Brentuximab Vedotin in Μycosis Fungoides and Sezary Syndrome patients with variable CD30 positivity

Quaglino, P;
2021-01-01

Abstract

Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial. Since then few real-life data are available.
2021
000
003
Brentuximab Vedotin; Cutaneous lymphoma; Mycosis Fungoides; Sezary Syndrome
Papadavid, E; Kapniari, E; Pappa, V; Nikolaou, V; Iliakis, T; Dalamaga, M; Jonak, C; Porkert, S; Engelina, S; Quaglino, P; Ortiz-Romero, P L; Vico, C;...espandi
03A-Articolo su Rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1792951
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact